GASTROGRAFIN®

Oral Solution

Sodium Amidotrizoate 100 mg/mL, Meglumine Amidotrizoate 660 mg/mL

Qualitative and Quantitative Composition

100 mL gastroenteral solution contains 10 g sodium amidotrizoate and 66 g meglumine amidotrizoate (sodium diatrizoate and meglumine diatrizoate).

For excipients, see Pharmaceutical Particulars, List of excipients.

Pharmaceutical Form

Gastroenteral solution.

Clinical Particulars

Indications

This medicinal product is for use by oral or rectal administration only.

Gastrografin is a contrast medium for the radiological examination of the gastrointestinal tract (also in combination with barium sulphate). It can be administered orally or as an enema and is primarily indicated in cases in which the use of barium sulphate is unsatisfactory, undesirable or contraindicated. These include:

- suspicion of a radiologically undetectable perforation or anastomotic defect in the oesophagus and/or gastrointestinal tract
- threatening perforation (peptic ulcer, diverticulum)
- prior resection of the stomach or the intestine (danger of perforation or leak)
- suspected partial or complete stenosis
- small bowel obstruction
- postoperative ileus
- acute haemorrhage
- other acute conditions which are likely to require surgery
- megacolon
- visualization of a foreign body or tumour before endoscopy
- visualisation of a gastrointestinal fistula
In addition to these situations, Gastrografin can generally be used for the same purposes as barium sulphate with the exception of the visualization of mucosal diseases. Due to the insufficient coating properties of Gastrografin, barium sulphate should be used for single or double contrast techniques.

In combination with barium sulphate, Gastrografin has considerably improved routine investigation of the gastrointestinal tract both from a diagnostic and from an organisational point of view - in the latter case by speeding up the examination. It is unsuitable only for the diagnosis of enteritis.

**Further indications:**

- treatment of uncomplicated meconium ileus
- computerised tomography in the abdominal region. The danger of incorrect diagnoses in computerised tomography in the abdominal regions is significantly reduced if the intestine is opacified with Gastrografin, especially for differential diagnoses in the minor pelvis. Gastrografin facilitates delimitation of the intestine from neighbouring organs and permits an assessment of changes in the shape of the pancreas.

**Dosage and Method of Administration**

**General Information**

Because of the additives (flavourings and a wetting agent), Gastrografin must not be used intravascularly.

**Dietary Suggestions**

Prior cleansing of the bowels enhances the diagnostic validity.

**Hydration**

Adequate hydration must be ensured before and after contrast medium administration. This applies especially to patients with multiple myeloma, diabetes mellitus with nephropathy, polyuria, oliguria, hyperuricemia, as well as to newborns, infants, small children and elderly patients. Disturbances of water and electrolyte balance must be corrected before the examination.

**Newborns (< 1 month), Infants (1 month - 2 years) and Children (2 - 11 years)**

Young infants (age < 1 year) and especially newborns are susceptible to electrolyte imbalance and haemodynamic alterations. Particular attention should be paid to the dose of contrast medium to be given, the technical performance of the radiological procedure and the patient status. Because of its high osmotic pressure and the tendency to absorption from the intestine, Gastrografin should not be administered to newborns, infants and young children in doses higher than those recommended. In newborns and infants
low osmolar contrast media can often be used more safely than the high osmolar Gastrografin.

**Dosage for Oral Use**

The dosage is dependent on the type of examination and the age of the patient.

**Adults and Children of 10 Years of Age and Over**

Visualization of the stomach: 60 mL

Follow-through examination of the gastrointestinal tract: a maximum of 100 mL

In adult patients and children of 10 years of age and over, 60 mL is sufficient for visualization of the stomach; for a follow-through examination of the gastrointestinal tract a maximum of 100 mL may be required. For elderly and cachectic patients dilution with an equal volume of water is recommended.

For the early diagnosis of a perforation or anastomosis in the oesophagus and/or gastrointestinal tract, the patient should drink up to 100 mL Gastrografin. If the suspected lesion cannot be clearly identified on the X-ray film, a chemical reaction can be employed for further clarification. After 30 - 60 minutes (later, if the defect is suspected of being in the distal gut), a urine specimen should be taken and 5 mL mixed with 5 drops of concentrated hydrochloric acid. The contrast medium which has undergone renal excretion will appear within 2 hours as a typical crystal formation in the precipitate.

**Children**

Newborns, infants and young children: 15 - 30mL (diluted with 3 times its volume of water)

Children (up to 10 years of age): 15 - 30mL (can be diluted with twice its volume of water)

In children up to 10 years of age, 15 - 30 mL is generally sufficient. This dose can be diluted with twice its volume of water. For newborns, infants and young children it is recommended that the contrast medium be diluted with 3 times its volume of water.

**Computerised Tomography (CT)**

0.5 - 1.5 litres of an approximately 3% Gastrografin solution (30 mL Gastrografin / 1 litre of water).

**Dosage for Rectal Use (including Therapy of Uncomplicated Meconium Ileus)**
Adults

Up to 500mL Gastrografin dilution (diluted with 3 - 4 times its volume of water)

For adult patients the contrast medium should be diluted with 3 - 4 times its volume of water. In general, unlike a barium sulphate enema, not more than 500 mL of this Gastrografin dilution is required.

Children

Children (up to 5 years of age): up to 500mL Gastrografin dilution (diluted with 5 times its volume of water)

Children (over 5 years of age): up to 500mL Gastrografin dilution (diluted with 4 - 5 times its volume of water)

For children over 5 years of age, the contrast medium should be diluted with 4 - 5 times its volume of water; for younger patients dilution with 5 times its volume of water is recommended.

Therapy of Meconium Ileus

Gastrografin can be given by enema for non-operative treatment of an uncomplicated meconium ileus. Advantage is taken of the high osmotic pressure of the contrast medium: the surrounding tissue is forced to release considerable amounts of fluid, which then flows into the gut and dissolves the inspissated (thickened or hardened) meconium.

Dosage for Gastrografin in Combination with Barium Sulphate

Adults and Children of 10 Years of Age and Over

In addition to the usual dose of barium sulphate: 30 mL Gastrografin

In adult patients and children of 10 years of age and over, addition of approximately 30 mL Gastrografin to the usual dose of barium sulphate has proved most satisfactory.

Children

In addition to the usual dose of barium sulphate:

Children (up to 5 years of age): 2 - 5 mL Gastrografin to 100 mL barium sulphate suspension

Children (from 5 - 10 years of age): 10 mL Gastrografin to 100 mL barium sulphate suspension

In children from 5 - 10 years of age, 10 mL Gastrografin may be added to the required amount of barium sulphate, in patients up to 5 years of age, addition of 2 - 5 mL Gastrografin to 100 mL barium sulphate suspension has proved of value.
If necessary (in cases of pylorospasm or pyloric stenosis), the portion of Gastrografin in the suspension may be further increased. This does not affect the contrast.

**Exposures**

Exposures of the stomach are taken in the usual way whether Gastrografin is used alone or in combination with barium sulphate.

The time taken for emptying of the stomach is the same as for barium sulphate whereas that for filling of the intestine is shorter. When Gastrografin is used alone, the contrast medium has generally reached the rectum after 2 hours, while the Gastrografin/barium sulphate mixture may take up to 3 hours, or longer in individual cases.

The most favourable time for taking exposures of the colon is indicated by the urge to defaecate which all patients experience.

**Contraindications**

Manifest hyperthyroidism.

Gastrografin must not be administered undiluted in patients with low plasma volume, as for example in newborns, infants, children and in dehydrated patients, since hypovolaemic complications can be particularly serious in these patients.

Gastrografin must not be administered undiluted in patients with suspected possibility of aspiration or broncho-oesophageal fistula, since hyperosmolarity may cause acute pulmonary oedema, chemical pneumonia, respiratory collapse and death.

**Special Warnings and Precautions for Use**

The following risks are higher in the case of intravascular administration of iodinated contrast media but are also relevant for the enteral use of Gastrografin.

**Hypersensitivity**

Particularly careful risk-benefit assessment is required in patients with known hypersensitivity to Gastrografin or any of its ingredients due to an increased risk for anaphylactoid/hypersensitivity reactions.

Patients with hypersensitivity or a previous reaction to iodinated contrast media are at increased risk of experiencing a severe reaction. However, such reactions are irregular and unpredictable in nature.
In patients with an allergic disposition, known hypersensitivity to iodinated contrast media or a history of asthma, premedication with antihistamines and/or glucocorticoids may be considered.

Patients with bronchial asthma are at particular risk of experiencing bronchospasms or hypersensitivity reactions.

As with other contrast agents, Gastrografin can be associated with anaphylactoid / hypersensitivity or other idiosyncratic reactions, characterised by cardiovascular, respiratory or cutaneous manifestations, and ranging to severe reactions including shock.

Delayed reactions may occur (hours later or up to several days) (see Undesirable Effects).

Nausea, vomiting, mild angioedema, conjunctivitis, coughing, pruritus, rhinitis, sneezing and urticaria have been reported. These reactions, which can occur irrespective of the amount administered and the mode of administration, may be the first signs of an incipient state of shock.

If hypersensitivity reactions occur (see Undesirable Effects), administration of the contrast medium must be discontinued immediately and, if necessary, specific therapy instituted via a venous access.

Medication for the treatment of hypersensitivity reactions as well as preparedness for institution of emergency measures are necessary.

The risk of anaphylactoid / hypersensitivity reactions is higher in case of:

- any history of allergic disorders
- history of bronchial asthma
- a previous anaphylactoid/hypersensitivity reaction to iodinated contrast media

Particularly careful risk - benefit assessment is required in patients with a previous anaphylactoid / hypersensitivity reaction to any other iodinated contrast medium because of an increased risk of anaphylactoid / hypersensitivity reactions in these patients.

Patients taking beta blockers who experience such reactions may be resistant to treatment with beta agonists.

Patients with cardiovascular disorders are more susceptible to serious or even fatal outcomes of severe anaphylactoid / hypersensitivity reactions.

**Thyroid Dysfunction**

Particularly careful risk- benefit assessment is required in patients with known or suspected hyperthyroidism or goitre, as iodinated contrast media may interfere with thyroid function, aggravate or induce hyperthyroidism and thyreotoxic crisis.
Testing of thyroid function prior to Gastrografin administration and/or preventive thyrostatic medication may be considered in patients with known or suspected hyperthyroidism.

**Very Poor State of Health**

The need for examination merits particularly careful consideration in patients with a very poor general state of health.

**Barium Sulfate**

If Gastrografin is used together with barium sulphate preparations, attention must be drawn to the contraindications, warnings and possible side effects relevant to the preparation.

**Gastrointestinal**

In case of prolonged retention of Gastrografin in the gastrointestinal tract (e.g. obstruction, stasis), tissue damage, bleeding, bowel necrosis and intestinal perforation may occur.

**Hydration**

Adequate hydration and electrolyte balance should be established and maintained in the patients, since the hyperosmolarity of Gastrografin may cause dehydration and electrolyte imbalance.

**Interaction with Other Medicinal Products and Other Forms of Interaction**

Hypersensitivity reactions can be aggravated in patients on beta - blockers, particularly in people with bronchial asthma. Patients who experience such reactions while taking beta blockers may be resistant to treatment of anaphylactoid / hypersensitivity reactions with beta agonists.

**Interleukin-2:** Previous treatment (up to several weeks) with interleukin-2 is associated with an increased risk of delayed reactions to Gastrografin.

**Interference with Diagnostic Tests**

**Radioisotopes:** Diagnosis and treatment of thyroid disorders with thyrotropic radioisotopes may be impeded for up to several weeks after administration of iodinated contrast agents due to reduced radioisotope uptake.

**Pregnancy and Lactation**

**Pregnancy**

Adequate and well-controlled studies in pregnant women have not been conducted.
Animal studies do not indicate direct or indirect harmful effects with respect to embryonal / foetal development (see Preclinical Safety Data).

Caution should be exercised when using Gastrografin in pregnant women. It has not yet been demonstrated that Gastrografin is safe for use in pregnant patients.

Since, wherever possible, radiation exposure should be avoided during pregnancy, the benefits of any X-ray examination, with or without contrast media, should be carefully weighed against the possible risk.

**Lactation**

No data exist regarding this application form in lactating women. After intravascular use, salts of the diatrizoic acid are excreted in human breast milk. However, at recommended doses of Gastrografin no effects on the breast-fed child are anticipated. Breast-feeding is probably safe, especially in view of the low enteral absorption of Gastrografin.

**Effects on Ability to Drive or Use Machines**

Not known.

**Undesirable Effects**

**Frequency of Adverse Reactions from Spontaneous Reports and Literature**

Undesirable effects in association with the use of iodinated contrast media are usually mild to moderate and transient in nature. However, severe and life-threatening reactions as well as deaths have been reported.

Vomiting, nausea and diarrhoea are the most frequently recorded reactions.

The table below reports adverse reactions by MedDRA system organ classes (MedDRA SOCs).

<table>
<thead>
<tr>
<th>System Organ Class</th>
<th>Common (≥ 1/100)</th>
<th>Rare (&lt; 1/1,000)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Immune system disorders</td>
<td></td>
<td>Anaphylactoid shock Anaphylactoid/hypersensitivity reaction</td>
</tr>
<tr>
<td>Endocrine disorders</td>
<td></td>
<td>Hyperthyroidism</td>
</tr>
<tr>
<td>Metabolism and nutrition disorders</td>
<td></td>
<td>Fluid and electrolyte imbalance</td>
</tr>
<tr>
<td>Nervous system disorders</td>
<td></td>
<td>Disturbances in consciousness Headache Dizziness</td>
</tr>
<tr>
<td>System Organ Class</td>
<td>Common (≥ 1/100)</td>
<td>Rare (&lt; 1/1,000)</td>
</tr>
<tr>
<td>--------------------</td>
<td>------------------</td>
<td>-----------------</td>
</tr>
<tr>
<td>Cardiac disorders</td>
<td>Cardiac arrest</td>
<td>Tachycardia</td>
</tr>
<tr>
<td>Vascular disorders</td>
<td>Shock</td>
<td>Hypotension</td>
</tr>
<tr>
<td>Respiratory, thoracic and mediastinal disorders</td>
<td>Bronchospasm</td>
<td>Dyspnœa</td>
</tr>
<tr>
<td></td>
<td>Medication aspiration</td>
<td>Pulmonary oedema following aspiration</td>
</tr>
<tr>
<td></td>
<td>Aspiration pneumonia</td>
<td></td>
</tr>
<tr>
<td>Gastrointestinal disorders</td>
<td>Vomiting</td>
<td>Intestinal perforation</td>
</tr>
<tr>
<td></td>
<td>Nausea</td>
<td>Abdominal pain</td>
</tr>
<tr>
<td></td>
<td>Diarrhoea</td>
<td>Oral mucosal blistering</td>
</tr>
<tr>
<td>Skin and subcutaneous tissue disorders</td>
<td>Toxic epidermal necrolysis</td>
<td>Urticaria</td>
</tr>
<tr>
<td></td>
<td>Rash</td>
<td>Pruritus</td>
</tr>
<tr>
<td></td>
<td>Erythema</td>
<td>Oedema face</td>
</tr>
<tr>
<td>General disorders and administration site conditions</td>
<td>Pyrexia</td>
<td>Sweating</td>
</tr>
</tbody>
</table>

The most appropriate MedDRA term is used to describe a certain reaction and its synonyms and related conditions.

**Immune System Disorders, Anaphylactoid Reaction / Hypersensitivity**

Systemic hypersensitivity is rare, mostly mild and occurs generally in the form of skin reactions. However, the possibility of a severe hypersensitivity reaction cannot be entirely excluded (see Special Warnings).

**Gastrointestinal Disorders**

The hypertonic Gastrografin solution may give rise to diarrhoea, but this ceases as soon as the intestine has been emptied. Existing enteritis or colitis may be temporarily exacerbated. In case of obstruction the prolonged contact with bowel mucosa can lead to erosions and to bowel necrosis.

**Overdose**

Disorders of water - and electrolyte balance caused by overdose should be corrected.

**Pharmacological Properties**
**Pharmacodynamic Properties**

The contrast-giving substance of Gastrografin is a salt of the amido(dia-)
trizoic acid in which the X-ray absorbing iodine is present in a stable chemical bond. The physico-chemical characteristics of Gastrografin are listed below:

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Iodine concentration (mg/mL)</td>
<td>370</td>
</tr>
<tr>
<td>Osmolality (osm/kg H₂O) at 37°C</td>
<td>2.15</td>
</tr>
<tr>
<td>Viscosity (mPa·s) at 20°C</td>
<td>18.5</td>
</tr>
<tr>
<td>Viscosity (mPa·s) at 37°C</td>
<td>8.9</td>
</tr>
<tr>
<td>Density (g/mL) at 20°C</td>
<td>1.427</td>
</tr>
<tr>
<td>Density (g/mL) at 37°C</td>
<td>1.417</td>
</tr>
<tr>
<td>pH-value</td>
<td>6.0 - 7.0</td>
</tr>
</tbody>
</table>

**Pharmacokinetic Properties**

Absorption of amidotrizoic acid, the radiopaque agent of Gastrografin, following oral administration is only 3%. Even in the absence of perforation, higher levels of absorption - demonstrated by opacification of the renal calyces and ureters - were observed in some patients.

If a perforation of the gastrointestinal tract is present, Gastrografin finds its way into the abdominal cavity or the surrounding tissue, where it is absorbed and finally excreted via the kidneys.

**Preclinical safety data**

The taste corrigents saccharin sodium and anise oil, the solubiliser polysorbate 80 as well as the stabilising additive disodium edetate contained in Gastrografin are considered to be toxicologically harmless at the doses used. Therefore, risk estimation was only performed for the contrast-giving compounds sodium- and meglumine amidotrizoate.

Non-clinical data reveal no special hazard for humans based on conventional studies of systemic toxicity, genotoxicity, toxicity to reproduction, local tolerance and contact - sensitizing potential.

**Systemic Toxicity**

Based on the results of preclinical acute toxicity studies, there is no risk of acute intoxication on use of Gastrografin.

Systemic tolerance studies following repeated oral administration have not been carried out and are not considered to be necessary. Only very small
amounts of amidotrizoate are systemically available. Systemic tolerance studies with meglumine- or sodium amidotrizoate following repeated daily intravenous administration produced no findings which argue against the single diagnostic intravenous dose generally administered to humans. Under the above-stated circumstances this is all the more true in the case of oral administration.

**Genotoxic Potential, Tumourigenicity**

Studies of genotoxic effects (gene-, chromosomal- and genome mutation tests) using the salt mixture sodium- and meglumine amidotrizoate *in vivo* and *in vitro* gave no indication of a mutagenic potential of Gastrografin.

Tumourigenicity studies have not been carried out. Due to the absence of genotoxic effects and taking into account the metabolic stability, pharmacokinetics and the absence of any indication of toxic effects of sodium- or meglumine amidotrizoate on fast-growing tissues, as well as the fact that Gastrografin is only administered once, there is no evident risk of a tumourigenic effect on humans.

**Toxicity to Reproduction**

Reproductive toxicology studies in animals with intravenous administration of meglumine- or sodium amidotrizoate gave no indication of a teratogenic or other embryotoxic potential. Due to the low resorption from the gastrointestinal tract (see systemic tolerance studies) no risk to either the pregnancy or the foetus is to be expected following inadvertent administration of Gastrografin during pregnancy.

**Local Tolerance and Contact-sensitizing Potential**

Local tolerance studies of Gastrografin on the mucous membranes in the gastrointestinal tract were not performed. However, local tolerance studies following intraperitoneal administration as well as administration into the oviduct using meglumine amidotrizoate gave no indication that adverse local effects on the mucous membranes of the human gastrointestinal tract are to be expected. This evaluation is supported by many years of clinical experience with Gastrografin.

Studies of contact-sensitizing effect gave no indication of a sensitizing potential of meglumine amidotrizoate. However, many years of clinical experience with Gastrografin show that the anaphylactoid reactions known to appear after other iodine-containing contrast media can occur.

---

**Pharmaceutical Particulars**

**Presentation**

Gastrografin is a clear, faintly yellowish, aqueous, ionic, hypertonic solution.
List of Excipients

Disodium edetate  
Sodium hydroxide  
Saccharin sodium  
Polysorbate 80  
Anise oil  
Purified water

Incompatibilities

Gastrografin must not be mixed with other medicinal products except those mentioned in the Dosage and Method of Administration section.

Special Precautions for Storage

Store at or below 25°C. Protect from light and X-rays.

Contrast medium solution not used within 72 hours after opening the bottle must be discarded.

Nature and Contents of Container

Bottles of 100 mL

Instructions for Use/Handling

At temperatures below 7°C Gastrografin tends to crystallise, but this can be reversed by gently warming and shaking the bottle. This phenomenon has no effect on the effectiveness or stability of the preparation.

Unused Gastrografin in opened containers must be discarded within 72 hours after first opening the container.

Medicine Classification

General Sales Medicine

Name and Address

Bayer New Zealand Limited  
3 Argus Place  
Hillcrest  
North Shore  
Auckland 0627

Free phone 0800 233 988
Date of Preparation

18 March 2010

Ref: Gastrografin Australian Approved Product Information from 9 April 2009.